IN2014DN03049A - - Google Patents

Info

Publication number
IN2014DN03049A
IN2014DN03049A IN3049DEN2014A IN2014DN03049A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A IN 3049DEN2014 A IN3049DEN2014 A IN 3049DEN2014A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A
Authority
IN
India
Prior art keywords
extracellular matrix
tissue
interstitial
expression
ecm
Prior art date
Application number
Inventor
Allison A Eddy
Daryl M Okamura
Original Assignee
Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Res Inst filed Critical Seattle Childrens Res Inst
Publication of IN2014DN03049A publication Critical patent/IN2014DN03049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition interstitial fibroblasts interstitial volume expression of Collagen I mRNA and protein expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
IN3049DEN2014 2011-10-26 2011-10-26 IN2014DN03049A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
IN2014DN03049A true IN2014DN03049A (en) 2015-05-15

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3049DEN2014 IN2014DN03049A (en) 2011-10-26 2011-10-26

Country Status (7)

Country Link
US (2) US9468612B2 (en)
AU (1) AU2011379972B2 (en)
BR (1) BR112014009789A2 (en)
CA (1) CA2853484C (en)
IN (1) IN2014DN03049A (en)
MX (1) MX2014004994A (en)
WO (1) WO2013062544A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759267B (en) * 2015-07-02 2022-04-01 美商地平線罕見醫學製藥有限責任公司 Ado-resistant cysteamine analogs and uses thereof
CA3017797A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
CA3052796A1 (en) * 2017-02-07 2018-08-16 Children's Hospital Medical Center Treatment of asthma with cysteamine
US11612576B2 (en) 2017-09-20 2023-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019094862A1 (en) * 2017-11-10 2019-05-16 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (en) 1983-06-22 1986-05-16 Centre Nat Rech Scient NOVEL RADIOPROTECTIVE AGENTS HAVING AN AMINO-THIOALKYL STRUCTURE AND PROCESS FOR THEIR PREPARATION
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
JP2887325B2 (en) 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション Inhibition of cell proliferation by decorin
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (en) 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション Inhibition of transforming growth factor-beta to prevent extracellular matrix accumulation
JPH05503003A (en) 1989-11-22 1993-05-27 ジェネンテク，インコーポレイテッド Potentially involved peptides and their uses
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
JP4124815B2 (en) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ TGF-β type receptor cDNA and use thereof
CA2123418A1 (en) 1991-11-14 1993-05-27 Erkki I. Ruoslahti Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
ES2174868T3 (en) 1992-10-29 2002-11-16 Celtrix Pharma FRAGMENT OF THE FIXING RECEIVER TO TGF-BETA TIPOII AS A THERAPEUTIC AGENT.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
EP0667870A4 (en) 1992-10-30 1998-04-01 Hsc Res Dev Lp COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF--g(b).
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
ATE208494T1 (en) 1994-05-04 2001-11-15 Mount Sinai Hospital Corp MODULATORS OF THE CYTOKINE OF THE TGF-BETA SUPERFAMILY AND METHOD FOR THEIR DETERMINATION
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (en) 1994-08-31 1996-05-14 Nkk Corp Actinomyces blonging to genus streptomyces and tgf-beta inhibitor derived from the same actinomyces
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (en) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk Abnormal accumulation suppressor of extracellular matrix
AU740052B2 (en) 1996-10-25 2001-10-25 Ethicon Inc. Anti-fibrotic agent assay
BR9808934A (en) 1997-04-18 2000-08-01 Biogen Inc Type II tgf-beta receptor / immunoglobulin constant region fusion proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE291020T1 (en) 2001-02-02 2005-04-15 Smithkline Beecham Corp PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION
JP2004521901A (en) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Pyrazoles as TGF inhibitors
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE368041T1 (en) 2001-05-24 2007-08-15 Lilly Co Eli NEW PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS
AR039241A1 (en) 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
EP1506191A1 (en) 2002-05-15 2005-02-16 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004024159A1 (en) 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
US7365066B2 (en) 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
AU2003268155A1 (en) 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
AU2003291642A1 (en) 2002-11-22 2004-06-18 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US20040127575A1 (en) 2002-11-22 2004-07-01 Feng Ying Method for counteracting a pathologic change in the beta-adrenergic pathway
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
EP1567527A1 (en) 2002-11-27 2005-08-31 Eli Lilly And Company Condensed pyrazolo derivatives
CA2513086A1 (en) 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
CL2004000234A1 (en) 2003-02-12 2005-04-15 Biogen Idec Inc DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
JP2006521398A (en) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド Bicyclic pyrimidine inhibitors of TGFβ
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
EP1708712A1 (en) 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
NZ550217A (en) 2004-03-31 2009-11-27 Genentech Inc Humanized anti-TGF-beta antibodies
DE102004019253A1 (en) 2004-04-16 2005-11-10 Codewrights Gmbh Method for remote control of a field device of process automation technology
CA2578628A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
JP2008511631A (en) 2004-08-31 2008-04-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Pyrimidinylimidazoles as TGF-β inhibitors
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
CN104151427B (en) 2005-02-08 2017-09-08 根茨美公司 For TGF β antibody
SI2535044T1 (en) 2006-01-27 2020-06-30 The Regents Of The University Of California Enterically coated cysteamine bitartrate and cystamine
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
DK2214480T3 (en) * 2007-11-30 2013-07-08 Univ California Methods for the treatment of nonalcoholic steatohepatitis (NASH) using cysteamine products

Also Published As

Publication number Publication date
CA2853484C (en) 2018-08-21
US20140275279A1 (en) 2014-09-18
AU2011379972A1 (en) 2014-05-15
CA2853484A1 (en) 2013-05-02
US20170165207A1 (en) 2017-06-15
US9468612B2 (en) 2016-10-18
US9925154B2 (en) 2018-03-27
AU2011379972B2 (en) 2016-05-12
MX2014004994A (en) 2014-08-27
BR112014009789A2 (en) 2017-04-25
WO2013062544A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
IN2014DN03049A (en)
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
IL226127A0 (en) Composition comprising proteins and oligosaccharides for treating skin diseases
MX353955B (en) Threads of cross-linked hyaluronic acid and methods of use thereof.
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
EP2648775A4 (en) Controller and power source for implantable blood pump
BR112013029800A2 (en) treatment of intervertebral disc degeneration with the use of cells derived from human umbilical cord tissue tissue
MX357749B (en) Treatment of pain using placental stem cells.
CL2013002601A1 (en) Use of 1-deoxigalactonojirimycin and an enzyme replacement therapy with alpha-gal a to treat fabry disease.
MX2015015536A (en) Wound healing and tissue engineering.
PL3087178T3 (en) Method for producing oxalate oxidases having activity optimum near physiological ph and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases
IL215467A0 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
MX2013008530A (en) Human lactoferrin based peptides having antiinflammatory activity.
EP2543396A4 (en) Artificial skin
EP2785356A4 (en) Use of pullulan for alleviating the appearance of scars or scar tissue
ZA201302638B (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
IL215406A0 (en) Electromedical device for the non-invasive reduction or removal of subcutaneous adipose tissue
WO2011038417A9 (en) Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation
EP3768264A4 (en) Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease
AU336535S (en) Medical dressing
AU336536S (en) Medical dressing
UA44660U (en) Method for treating systemic diseases of connective tissue with predominant skin lesions
AU2010905197A0 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
UA99774C2 (en) Treatment of inflammatory diseases with mammal beta defensins